BRAF and melanoma: Collectively, these data highlight a role for CDK4/6 in metabolic reprogramming in a range of contexts and cancer settings; however, there has been no previous report of how CDK4/6 regulates metabolism in the setting of melanoma, nor of how CDK4/6 influences the metabolic response to BRAF/MAPK pathway targeted therapies.